Sugi Predict

Sugi Predict / Targets / MAP2K7

MAP2K7

Dual specificity mitogen-activated protein kinase kinase 7 · O14733 · MAP2K7 on Sugi Atlas →

15,184 patent compounds predicted against MAP2K7, 11,074 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1140184 SCHEMBL1140184 0.62 13/20
SCHEMBL722298 SCHEMBL722298 0.47 11/20
SCHEMBL721788 SCHEMBL721788 0.50 10/20
SCHEMBL1140183 SCHEMBL1140183 0.50 10/20
SCHEMBL1287111 SCHEMBL1287111 1.00 6/20
SCHEMBL690191 SCHEMBL690191 0.60 6/20
SCHEMBL1460719 SCHEMBL1460719 0.51 6/20
SCHEMBL1330118 SCHEMBL1330118 0.47 6/20
SCHEMBL690579 SCHEMBL690579 0.59 5/20
SCHEMBL1460678 SCHEMBL1460678 0.53 5/20
SCHEMBL1460931 SCHEMBL1460931 0.53 5/20
SCHEMBL1460974 SCHEMBL1460974 0.51 5/20
SCHEMBL1137054 SCHEMBL1137054 0.49 5/20
SCHEMBL686744 SCHEMBL686744 0.48 5/20
SCHEMBL1102013 SCHEMBL1102013 0.46 5/20
SCHEMBL723784 SCHEMBL723784 0.43 5/20
SCHEMBL374583 SCHEMBL374583 0.40 5/20
SCHEMBL1460692 SCHEMBL1460692 0.66 4/20
SCHEMBL1460786 SCHEMBL1460786 0.59 4/20
SCHEMBL571026 SCHEMBL571026 0.58 4/20

Clinical trials — most relevant to MAP2K7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations PHASE1SUSPENDED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Phase I Trial of VS-6766 Alone and in Combination With Everolimus PHASE1COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP2K7 binder may also engage these)

ProteinNameSimilarity
Q4KSH7 — 1.000 Q4KSH7 →
Q90321 — 0.996 Q90321 →
Q90891 — 0.995 Q90891 →
P31938 — 0.994 P31938 →
PAK3 Serine/threonine-protein kinase PAK 3 0.994 landscape →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.994 landscape →
Q63980 — 0.993 Q63980 →
Q20347 — 0.993 Q20347 →
Q07192 — 0.993 Q07192 →
Q91447 — 0.993 Q91447 →
Q1HG70 — 0.993 Q1HG70 →
Q9Y884 — 0.993 Q9Y884 →
Q9XT09 — 0.993 Q9XT09 →
PAK2 Serine/threonine-protein kinase PAK 2 0.993 landscape →
P36506 — 0.993 P36506 →
Q24324 — 0.992 Q24324 →
STK24 Serine/threonine-protein kinase 24 0.992 landscape →
P35465 — 0.992 P35465 →
Q99KH8 — 0.992 Q99KH8 →
Q7YQL4 — 0.992 Q7YQL4 →
Q9NB31 — 0.992 Q9NB31 →
P47809 — 0.991 P47809 →
Q08E52 — 0.991 Q08E52 →
Q05116 — 0.991 Q05116 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.991 landscape →
Q5QN75 — 0.990 Q5QN75 →
O88643 — 0.990 O88643 →
Q10664 — 0.990 Q10664 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.990 landscape →
O80396 — 0.990 O80396 →